Guo M, VanderWalde AM, Yu X, Vidal GA, et al. Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events. Clin Lung Cancer 2022 Aug 8. pii: S1525-7304(22)00166.
PMID: 36050243